

April 16, 2018



DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

- Update on Ongoing MGMT-unmethylated Clinical Trials to be Presented on Tuesday April 17, 2018 -

VANCOUVER, British Columbia and MENLO PARK, Calif., April 16, 2018 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced four poster presentations being delivered at the American Association for Cancer Research ("AACR") annual meeting.

On Sunday, April 15, 2018, DelMar presented a poster showing preclinical data demonstrating that VAL-083, a first-in-class small molecule chemotherapeutic, may be beneficial, either as a single-agent, or as part of combination therapy regimens, for difficult-to-treat, or resistant, pediatric high-grade gliomas, including diffuse intrinsic pontine glioma ("DIPG"). DIPG is a rare, inoperable childhood brain tumor with very poor prognosis and a bleak survival outlook. In a poster entitled, "Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG," VAL-083 is shown to be active as a single-agent and synergistic with AZD1775, a Wee1 inhibitor, against DIPG cell lines with varying genetic profiles, including p53 and H3.3/H3.1 K27M mutations.

Today, DelMar will be presenting a poster showing preclinical data demonstrating that the combination of VAL-083 and PARP inhibitors may be an effective therapeutic approach for the treatment of cancer. The data show that VAL-083 can synergize PARP inhibitors in both a BRACA-proficient and –deficient setting. Multiple PARP inhibitors are currently approved for the treatment of recurrent breast and ovarian cancer. DelMar also presented data in this poster further demonstrating that VAL-083 is active as a single-agent against platinum-resistant ovarian cancer.

"These important data continue to support the broad potential of VAL-083 to provide a new treatment option against a range of cancers," said Saiid Zarrabian, DelMar's interim president and chief executive officer. "Our ongoing clinical trials in MGMT-unmethylated GBM and planned trial in platinum-resistant ovarian cancer continue to leverage insights gained through more than 40 Phase 1 and Phase 2 clinical trials sponsored by the U.S. National Cancer Institute."

DelMar will present an update on two ongoing clinical trials for MGMT-unmethylated GBM

tomorrow, Tuesday April 17, 2018:

- A Phase 2 clinical trial of VAL-083 in patients with MGMT-unmethylated, bevacizumab (Avastin)-naïve recurrent glioblastoma, currently being conducted in collaboration with the University of Texas MD Anderson Cancer Center; and
- A Phase 1-2 clinical trial of VAL-083 in combination with radiotherapy in patients with newly diagnosed MGMT-unmethylated GBM, currently being conducted in collaboration with Sun Yat-sen University Cancer Center.

DelMar's poster presentations can be viewed on the company's website at:

<http://www.delmarpharma.com/scientific-publications.html>

About VAL-083

VAL-083 (dianhydrogalactitol) is a "first-in-class," DNA-targeting agent that introduces interstrand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute ("NCI"). DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by common mechanisms of chemoresistance *in vitro*. Further details regarding these studies can be found at:

<http://www.delmarpharma.com/scientific-publications.html>.

VAL-083 has been granted an orphan drug designation by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas. VAL-083 has been granted fast-track status for the treatment of recurrent GBM by the US FDA.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. By developing an understanding of tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or have become intolerable to, modern targeted or biologic treatments.

The Company's current pipeline centers around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the NCI. Based on DelMar's internal research programs and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 across multiple oncology indications to solve significant unmet medical needs.

DelMar is currently studying VAL-083 in two collaborator-supported, biomarker driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM. DelMar also recently announced the allowance of a separate IND for VAL-083 as a potential

treatment for platinum-resistant ovarian cancer.

Further information on DelMar's clinical trials can be found on clinicaltrials.gov:

<https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs>

For further information, please visit <http://delmarpharma.com/>; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.

Connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

View original content with multimedia: <http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-multiple-presentations-at-annual-meeting-of-the-american-association-for-cancer-research-300630073.html>

SOURCE DelMar Pharmaceuticals, Inc.